{
  "fullName": "Rajendra Badwe",
  "slug": "rajendra-badwe",
  "title": "MD",
  "specialty": "Breast oncology",
  "geography": {
    "country": "Global",
    "city": "Unknown",
    "region": "Unknown"
  },
  "status": "LIVING",
  "tier": "UNRANKED",
  "rankingScore": 26.44,
  "hIndex": 74,
  "yearsActive": 0,
  "verifiedSurgeries": 0,
  "livesSaved": 0,
  "biography": "Rajendra Achyut Badwe, is an Indian medical doctor and surgical oncologist. He was honoured by the Government of India, in 2013, by bestowing on him the Padma Shri, the fourth highest civilian award, for his contributions to the field of medicine. He is the former Director of Tata Memorial Centre, succeeded by Sudeep Gupta",
  "aiSummary": "Rajendra Badwe is a breast oncology specialist with an H-index of 74 at Tata Memorial (Member). Has been published in New England Journal of Medicine, The Lancet, The Lancet Oncology. Based in Unknown, Unknown, Global.",
  "techniquesInvented": [],
  "hasInvention": false,
  "education": [
    "Tata Memorial"
  ],
  "socialMedia": {},
  "affiliations": [
    {
      "hospitalName": "Tata Memorial",
      "role": "Member",
      "hospitalUrl": "#"
    }
  ],
  "medicalSpecialty": [
    "Breast oncology"
  ],
  "knowsAbout": [],
  "citations": [
    {
      "title": "Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer",
      "journal": "New England Journal of Medicine",
      "year": 2011,
      "citationCount": 2474,
      "doi": "10.1056/nejmoa1113216",
      "sourceUrl": "https://doi.org/10.1056/nejmoa1113216",
      "verified": true
    },
    {
      "title": "Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer",
      "journal": "New England Journal of Medicine",
      "year": 2022,
      "citationCount": 2321,
      "doi": "10.1056/nejmoa2203690",
      "sourceUrl": "https://doi.org/10.1056/nejmoa2203690",
      "verified": true
    },
    {
      "title": "Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer",
      "journal": "New England Journal of Medicine",
      "year": 2015,
      "citationCount": 2048,
      "doi": "10.1056/nejmoa1413513",
      "sourceUrl": "https://doi.org/10.1056/nejmoa1413513",
      "verified": true
    },
    {
      "title": "Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer",
      "journal": "New England Journal of Medicine",
      "year": 2015,
      "citationCount": 1994,
      "doi": "10.1056/nejmoa1406470",
      "sourceUrl": "https://doi.org/10.1056/nejmoa1406470",
      "verified": true
    },
    {
      "title": "Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer",
      "journal": "New England Journal of Medicine",
      "year": 2019,
      "citationCount": 1846,
      "doi": "10.1056/nejmoa1914510",
      "sourceUrl": "https://doi.org/10.1056/nejmoa1914510",
      "verified": true
    },
    {
      "title": "Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy",
      "journal": "New England Journal of Medicine",
      "year": 2017,
      "citationCount": 1818,
      "doi": "10.1056/nejmoa1612645",
      "sourceUrl": "https://doi.org/10.1056/nejmoa1612645",
      "verified": true
    },
    {
      "title": "Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study",
      "journal": "The Lancet",
      "year": 2018,
      "citationCount": 1634,
      "doi": "10.1016/s0140-6736(18)31999-8",
      "sourceUrl": "https://doi.org/10.1016/s0140-6736(18)31999-8",
      "verified": true
    },
    {
      "title": "Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study",
      "journal": "The Lancet",
      "year": 2021,
      "citationCount": 1470,
      "doi": "10.1016/s0140-6736(21)01234-4",
      "sourceUrl": "https://doi.org/10.1016/s0140-6736(21)01234-4",
      "verified": true
    },
    {
      "title": "Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial",
      "journal": "The Lancet Oncology",
      "year": 2019,
      "citationCount": 1190,
      "doi": "10.1016/s1470-2045(19)30626-6",
      "sourceUrl": "https://doi.org/10.1016/s1470-2045(19)30626-6",
      "verified": true
    },
    {
      "title": "Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer",
      "journal": "Journal of Clinical Oncology",
      "year": 2020,
      "citationCount": 1128,
      "doi": "10.1200/jco.20.01888",
      "sourceUrl": "https://doi.org/10.1200/jco.20.01888",
      "verified": true
    },
    {
      "title": "Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study",
      "journal": "The Lancet Oncology",
      "year": 2013,
      "citationCount": 984,
      "doi": "10.1016/s1470-2045(13)70130-x",
      "sourceUrl": "https://doi.org/10.1016/s1470-2045(13)70130-x",
      "verified": true
    },
    {
      "title": "Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study",
      "journal": "The Lancet Oncology",
      "year": 2020,
      "citationCount": 853,
      "doi": "10.1016/s1470-2045(19)30863-0",
      "sourceUrl": "https://doi.org/10.1016/s1470-2045(19)30863-0",
      "verified": true
    },
    {
      "title": "Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial",
      "journal": "The Lancet Oncology",
      "year": 2014,
      "citationCount": 704,
      "doi": "10.1016/s1470-2045(14)70178-0",
      "sourceUrl": "https://doi.org/10.1016/s1470-2045(14)70178-0",
      "verified": true
    },
    {
      "title": "Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up",
      "journal": "Annals of Oncology",
      "year": 2023,
      "citationCount": 668,
      "doi": "10.1016/j.annonc.2023.11.016",
      "sourceUrl": "https://doi.org/10.1016/j.annonc.2023.11.016",
      "verified": true
    },
    {
      "title": "Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial",
      "journal": "Journal of Clinical Oncology",
      "year": 2020,
      "citationCount": 586,
      "doi": "10.1200/jco.20.00147",
      "sourceUrl": "https://doi.org/10.1200/jco.20.00147",
      "verified": true
    },
    {
      "title": "Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial",
      "journal": "The Lancet",
      "year": 2022,
      "citationCount": 578,
      "doi": "10.1016/s0140-6736(22)02420-5",
      "sourceUrl": "https://doi.org/10.1016/s0140-6736(22)02420-5",
      "verified": true
    },
    {
      "title": "Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial",
      "journal": "The Lancet Oncology",
      "year": 2017,
      "citationCount": 577,
      "doi": "10.1016/s1470-2045(17)30717-9",
      "sourceUrl": "https://doi.org/10.1016/s1470-2045(17)30717-9",
      "verified": true
    },
    {
      "title": "Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer",
      "journal": "Breast Cancer Research and Treatment",
      "year": 2007,
      "citationCount": 518,
      "doi": "10.1007/s10549-007-9591-y",
      "sourceUrl": "https://doi.org/10.1007/s10549-007-9591-y",
      "verified": true
    },
    {
      "title": "Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus",
      "journal": "JAMA Oncology",
      "year": 2018,
      "citationCount": 510,
      "doi": "10.1001/jamaoncol.2018.5441",
      "sourceUrl": "https://doi.org/10.1001/jamaoncol.2018.5441",
      "verified": true
    },
    {
      "title": "Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial",
      "journal": "The Lancet Oncology",
      "year": 2017,
      "citationCount": 502,
      "doi": "10.1016/s1470-2045(17)30313-3",
      "sourceUrl": "https://doi.org/10.1016/s1470-2045(17)30313-3",
      "verified": true
    },
    {
      "title": "Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial",
      "journal": "UNC Libraries",
      "year": 2020,
      "citationCount": 486,
      "doi": "10.17615/tfn3-9835",
      "sourceUrl": "https://doi.org/10.17615/tfn3-9835",
      "verified": true
    },
    {
      "title": "Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial",
      "journal": "The Lancet Oncology",
      "year": 2017,
      "citationCount": 461,
      "doi": "10.1016/s1470-2045(17)30450-3",
      "sourceUrl": "https://doi.org/10.1016/s1470-2045(17)30450-3",
      "verified": true
    },
    {
      "title": "Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response",
      "journal": "The Lancet Oncology",
      "year": 2014,
      "citationCount": 451,
      "doi": "10.1016/s1470-2045(14)70320-1",
      "sourceUrl": "https://doi.org/10.1016/s1470-2045(14)70320-1",
      "verified": true
    },
    {
      "title": "Synergistic antibacterial effect of curcumin against methicillin-resistant Staphylococcus aureus",
      "journal": "Phytomedicine",
      "year": 2013,
      "citationCount": 445,
      "doi": "10.1016/j.phymed.2013.02.006",
      "sourceUrl": "https://doi.org/10.1016/j.phymed.2013.02.006",
      "verified": true
    },
    {
      "title": "Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial",
      "journal": "The Lancet Oncology",
      "year": 2020,
      "citationCount": 363,
      "doi": "10.1016/s1470-2045(20)30465-4",
      "sourceUrl": "https://doi.org/10.1016/s1470-2045(20)30465-4",
      "verified": true
    },
    {
      "title": "Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes",
      "journal": "Human Pathology",
      "year": 2006,
      "citationCount": 357,
      "doi": "10.1016/j.humpath.2006.04.015",
      "sourceUrl": "https://doi.org/10.1016/j.humpath.2006.04.015",
      "verified": true
    },
    {
      "title": "Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial",
      "journal": "The Lancet Oncology",
      "year": 2012,
      "citationCount": 336,
      "doi": "10.1016/s1470-2045(12)70329-7",
      "sourceUrl": "https://doi.org/10.1016/s1470-2045(12)70329-7",
      "verified": true
    },
    {
      "title": "Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer",
      "journal": "JAMA Oncology",
      "year": 2021,
      "citationCount": 336,
      "doi": "10.1001/jamaoncol.2020.7932",
      "sourceUrl": "https://doi.org/10.1001/jamaoncol.2020.7932",
      "verified": true
    },
    {
      "title": "Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial",
      "journal": "The Lancet",
      "year": 2023,
      "citationCount": 313,
      "doi": "10.1016/s0140-6736(23)00725-0",
      "sourceUrl": "https://doi.org/10.1016/s0140-6736(23)00725-0",
      "verified": true
    },
    {
      "title": "Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer",
      "journal": "JAMA Oncology",
      "year": 2016,
      "citationCount": 309,
      "doi": "10.1001/jamaoncol.2016.0237",
      "sourceUrl": "https://doi.org/10.1001/jamaoncol.2016.0237",
      "verified": true
    },
    {
      "title": "Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial",
      "journal": "Journal of Clinical Oncology",
      "year": 2021,
      "citationCount": 309,
      "doi": "10.1200/jco.20.03639",
      "sourceUrl": "https://doi.org/10.1200/jco.20.03639",
      "verified": true
    },
    {
      "title": "Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study",
      "journal": "Journal of Clinical Oncology",
      "year": 2022,
      "citationCount": 288,
      "doi": "10.1200/jco.21.01926",
      "sourceUrl": "https://doi.org/10.1200/jco.21.01926",
      "verified": true
    },
    {
      "title": "Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial",
      "journal": "The Lancet Oncology",
      "year": 2020,
      "citationCount": 250,
      "doi": "10.1016/s1470-2045(20)30112-1",
      "sourceUrl": "https://doi.org/10.1016/s1470-2045(20)30112-1",
      "verified": true
    },
    {
      "title": "Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial",
      "journal": "The Lancet Oncology",
      "year": 2017,
      "citationCount": 214,
      "doi": "10.1016/s1470-2045(17)30064-5",
      "sourceUrl": "https://doi.org/10.1016/s1470-2045(17)30064-5",
      "verified": true
    },
    {
      "title": "Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase III KEYNOTE-181 study.",
      "journal": "Journal of Clinical Oncology",
      "year": 2019,
      "citationCount": 207,
      "doi": "10.1200/jco.2019.37.4_suppl.2",
      "sourceUrl": "https://doi.org/10.1200/jco.2019.37.4_suppl.2",
      "verified": true
    },
    {
      "title": "Covered Retrievable Expandable Nitinol Stents in Patients with Benign Esophageal Strictures: Initial Experience",
      "journal": "Radiology",
      "year": 2000,
      "citationCount": 199,
      "doi": "10.1148/radiology.217.2.r00nv03551",
      "sourceUrl": "https://doi.org/10.1148/radiology.217.2.r00nv03551",
      "verified": true
    },
    {
      "title": "Tipifarnib in Head and Neck Squamous Cell Carcinoma With<i>HRAS</i>Mutations",
      "journal": "Journal of Clinical Oncology",
      "year": 2021,
      "citationCount": 184,
      "doi": "10.1200/jco.20.02903",
      "sourceUrl": "https://doi.org/10.1200/jco.20.02903",
      "verified": true
    },
    {
      "title": "Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study",
      "journal": "The Lancet Oncology",
      "year": 2023,
      "citationCount": 174,
      "doi": "10.1016/s1470-2045(23)00275-9",
      "sourceUrl": "https://doi.org/10.1016/s1470-2045(23)00275-9",
      "verified": true
    },
    {
      "title": "HER2+ breast cancer treatment and cardiotoxicity: monitoring and management",
      "journal": "Breast Cancer Research and Treatment",
      "year": 2019,
      "citationCount": 171,
      "doi": "10.1007/s10549-019-05303-y",
      "sourceUrl": "https://doi.org/10.1007/s10549-019-05303-y",
      "verified": true
    },
    {
      "title": "<sup>18</sup>F-FDG PET/CT for Early Prediction of Response to Neoadjuvant Lapatinib, Trastuzumab, and Their Combination in HER2-Positive Breast Cancer: Results from Neo-ALTTO",
      "journal": "Journal of Nuclear Medicine",
      "year": 2013,
      "citationCount": 157,
      "doi": "10.2967/jnumed.112.119271",
      "sourceUrl": "https://doi.org/10.2967/jnumed.112.119271",
      "verified": true
    },
    {
      "title": "Brain metastases in breast cancer: prognostic factors and management",
      "journal": "Breast Cancer Research and Treatment",
      "year": 2007,
      "citationCount": 156,
      "doi": "10.1007/s10549-007-9806-2",
      "sourceUrl": "https://doi.org/10.1007/s10549-007-9806-2",
      "verified": true
    },
    {
      "title": "Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer",
      "journal": "JAMA",
      "year": 2024,
      "citationCount": 156,
      "doi": "10.1001/jama.2024.3056",
      "sourceUrl": "https://doi.org/10.1001/jama.2024.3056",
      "verified": true
    },
    {
      "title": "A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer",
      "journal": "European Journal of Cancer",
      "year": 2013,
      "citationCount": 151,
      "doi": "10.1016/j.ejca.2013.07.142",
      "sourceUrl": "https://doi.org/10.1016/j.ejca.2013.07.142",
      "verified": true
    },
    {
      "title": "How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies",
      "journal": "ESMO Open",
      "year": 2018,
      "citationCount": 146,
      "doi": "10.1136/esmoopen-2018-000357",
      "sourceUrl": "https://doi.org/10.1136/esmoopen-2018-000357",
      "verified": true
    },
    {
      "title": "Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates",
      "journal": "JAMA Oncology",
      "year": 2021,
      "citationCount": 141,
      "doi": "10.1001/jamaoncol.2021.3595",
      "sourceUrl": "https://doi.org/10.1001/jamaoncol.2021.3595",
      "verified": true
    },
    {
      "title": "Safety and Efficacy of Neratinib in Combination With Capecitabine in Patients With Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer",
      "journal": "Journal of Clinical Oncology",
      "year": 2014,
      "citationCount": 136,
      "doi": "10.1200/jco.2014.56.3809",
      "sourceUrl": "https://doi.org/10.1200/jco.2014.56.3809",
      "verified": true
    },
    {
      "title": "Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial",
      "journal": "The Lancet Oncology",
      "year": 2015,
      "citationCount": 126,
      "doi": "10.1016/s1470-2045(15)00373-3",
      "sourceUrl": "https://doi.org/10.1016/s1470-2045(15)00373-3",
      "verified": true
    },
    {
      "title": "Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial",
      "journal": "The Lancet Oncology",
      "year": 2019,
      "citationCount": 120,
      "doi": "10.1016/s1470-2045(19)30565-0",
      "sourceUrl": "https://doi.org/10.1016/s1470-2045(19)30565-0",
      "verified": true
    },
    {
      "title": "Value of complete metabolic response by 18F-fluorodeoxyglucose-positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy",
      "journal": "European Journal of Cancer",
      "year": 2007,
      "citationCount": 117,
      "doi": "10.1016/j.ejca.2007.04.001",
      "sourceUrl": "https://doi.org/10.1016/j.ejca.2007.04.001",
      "verified": true
    },
    {
      "title": "Diagnostic accuracy and safety of 16α-[18F]fluoro-17β-oestradiol PET-CT for the assessment of oestrogen receptor status in recurrent or metastatic lesions in patients with breast cancer: a prospective cohort study",
      "journal": "The Lancet Oncology",
      "year": 2019,
      "citationCount": 114,
      "doi": "10.1016/s1470-2045(18)30936-7",
      "sourceUrl": "https://doi.org/10.1016/s1470-2045(18)30936-7",
      "verified": true
    }
  ],
  "awards": [],
  "timeline": [],
  "openalexId": "https://openalex.org/A5026459010"
}